Morgan Stanley Global Endurance Portfolio Class C (MSJCX)
| Fund Assets | 16.89M |
| Expense Ratio | 2.10% |
| Min. Investment | $1,000 |
| Turnover | 176.00% |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Dividend Growth | n/a |
| Payout Frequency | n/a |
| Ex-Dividend Date | n/a |
| Previous Close | 19.04 |
| YTD Return | -2.56% |
| 1-Year Return | 25.43% |
| 5-Year Return | -37.52% |
| 52-Week Low | 13.58 |
| 52-Week High | 20.02 |
| Beta (5Y) | n/a |
| Holdings | 26 |
| Inception Date | Dec 31, 2018 |
About MSJCX
Morgan Stanley Global Endurance Portfolio C is an actively managed mutual fund focused on achieving long-term capital appreciation. The portfolio primarily targets high-quality established and emerging companies across global markets, with a particular emphasis on firms exhibiting durable competitive advantages, strong management teams, and attractive long-term growth prospects. The fund spans multiple sectors and industries, investing mainly in global small- and mid-cap equities, and is guided by rigorous fundamental analysis to select companies with robust business models and solid growth opportunities. With a relatively concentrated portfolio structure—typically holding around 31 stocks—the fund maintains a high active share compared to broader benchmarks, such as the MSCI All Country World Index. It is characterized by higher volatility and portfolio turnover, reflecting its active pursuit of growth opportunities worldwide. The expense ratio is above the category average, and Class C shares may include distribution and deferred sales charges. The Morgan Stanley Global Endurance Portfolio C plays a niche role in the market, offering investors focused exposure to global growth companies outside the large-cap segment.
Performance
MSJCX had a total return of 25.43% in the past year, including dividends. Since the fund's inception, the average annual return has been 11.17%.
Top 10 Holdings
62.57% of assets| Name | Symbol | Weight |
|---|---|---|
| Morgan Stanley Treasury Sec Morgan Stanley Treas Msuxx | n/a | 10.76% |
| Victoria PLC | VCP.L | 7.44% |
| Roivant Sciences Ltd. | ROIV | 7.17% |
| QXO, Inc. | QXO | 5.80% |
| Teva Pharmaceutical Industries Limited | TEVA | 5.78% |
| ABIVAX Société Anonyme | ABVX | 5.58% |
| Teleflex Incorporated | TFX | 5.52% |
| Immunovant, Inc. | IMVT | 5.20% |
| Arbutus Biopharma Corporation | ABUS | 4.99% |
| Belite Bio, Inc | BLTE | 4.33% |